International Cancer & Oncology Conference

July 22-23, 2024 | Zurich, Switzerland

Theme – Current trends & concepts in the field of cancer and oncology

Venue : Hilton Garden Inn Zurich Limmattal

Organizing Committee

Check out our OCM

Submit Abstract

Submit Research Article

Early Bird Registration

Expiring on April 28, 2024

Download Brochure Now

About Cancer & Oncology

Come join us at the “Cancer & Oncology” Conference taking place on July 22-23, 2024, in Zurich, Switzerland. Themed “Cancer & Oncology Disease: Challenges and Breakthroughs,” this international gathering warmly welcomes researchers, professors, clinicians, and professionals specializing in Cancer & Oncology. Engage in discussions on current challenges, share groundbreaking research, and forge connections with leading experts in oncology and related fields. Make sure not to miss Cancer Conference 2024 for in-depth conversations on the latest developments in Cancer & Oncology.

Join us at the “Cancer & Oncology” Conference in Zurich, Switzerland, July 22-23, 2024, for discussions on challenges and breakthroughs.

Speaker

Michal Linial

Hebrew University of Jerusalem, Israel

Nabil Djouder

University of Freiburg, Germany.

Joseph Yanai

University of Colorado, US

Rony Seger

weizmann institute of science, Isreal

Cancer & Oncology Scientific Sessions

01. Oncology

02. Cancer Biology

03. Cancer Diagnosis & Treatment

04. Prevention of Cancer

05. Breast Cancer

06. Palliative Care

07. Clinical Oncology

08. Head & Neck Cancer

Who to attend Cancer Oncology Conferences?

Why to attend Cancer Oncology Conferences?

Conferences Events Venue - Zurich

Zurich, Switzerland’s largest city and capital of the canton of Zürich, sits in an Alpine setting at Lake Zurich’s northwestern end. A hub of finance, culture, and industry, it sprawls between forested hills. With a diverse ethnic makeup—over one-third immigrants—it’s among Switzerland’s most cosmopolitan cities. Zurich’s architectural marvels line the Limmat River’s banks, especially in the vibrant Altstadt (Old Town). Here, Charlemagne’s Romanesque Grossmunster, 13th-century St. Peter’s Church, and ornate guild houses stand testament to its history. Beyond, surprises await, from cultural richness to culinary delights. Zurich captivates with its blend of heritage and modernity, making it a must-visit destination for travelers Conferences seeking both tradition and innovation.

sustainable development conferences

Media Partners & Collaborations Events

Event Summary

Conferences serve as essential platforms for academic researchers and business executives alike. They encompass various elements, including numerous presentations, interactive breakout sessions, hands-on product demonstrations, and unparalleled networking opportunities.

We’ve extended invitations to globally renowned keynote speakers, experts, brand ambassadors, and industry leaders, who will graciously share their insights and ideas with our esteemed conference attendees.

Payment for Stripe conferences registrations Congress can only be made by credit card or debit card online and the listed payment applications.Cancer Conferences Congress

FIVE REASONS WHY YOU NEED TO GO TO THE CANCER & ONCOLOGY CONFERENCE. Find out about the many future scopes. Convert technology advancements into therapeutic uses that apply to day-to-day operations. Make contact and communicate with developers of technologies. These Stripe Conferences provide a platform where experts in the field share their knowledge and expertise, allowing attendees to learn from industry leaders, but attending International conferences also provides a unique networking opportunity. By connecting with like-minded professionals, you can expand your professional network and potentially collaborate on future projects. Moreover, Cancer Oncology help you stay up-to-date with the latest trends and developments in your industry. With technology constantly evolving, attending these conferences ensures that you are always aware of the latest advances in the field of Cancer and Oncology. So why miss out on such a valuable opportunity? Attend Cancer and Oncology conferences and stay at the forefront of your industry.

The Stripe Conferences is organized by the Stripe journal Cancer & Oncology will take place virtually on July 22-23, 2024 Zurich, Switzerland.

Conferences Scientific Sessions list : 

    • Oncology
    • Cancer Biology
    • Cancer Diagnosis & Treatment
    • Prevention of Cancer
    • Clinical Oncology
    • Head & Neck Cancer
    • Breast Cancer
    • Palliative Care
    • Innovations In Cancer Research
    • Biomarkers in Cancer Stem Cells
    • Oncology Nursing
    • Skin Cancer

Welcome to the Stripe Conferences on the Future of Cancer & Oncology, which will be held on July 22-23, 2024 in the city of Zurich, Switzerland.!

Join us at Stripe Conferences for Cancer Conferences 2024. Download the brochure to access essential information on speakers, guidelines, and the tentative program for this exciting event.

Upcoming Conferences 2024

Contact Us

If you ever need assistance or have questions, please don’t hesitate to reach out to our dedicated support team.
Call Back Request

WhatsApp Now

We use essential cookies to make our site work. With your consent, we may also use non-essential cookies to improve user experience and analyze website traffic. By clicking “Accept,” you agree to our website's cookie use as described in our Cookie Policy. You can change your cookie settings at any time by clicking “Preferences.”

Michal Linial

Hebrew University of Jerusalem, Israel

Professor of Biochemistry and Bioinformatics at the Hebrew University of Jerusalem (HUJI).[3] Linial is the Director of The Sudarsky Center for Computational Biology at HUJI.[4][5] Since 2015, she is head of the ELIXIR-Israel node (European life-sciences Infrastructure for biological Information).[6]Linial was elected a fellow of the International Society for Computational Biology (ISCB) in 2016, for outstanding contributions to the fields of computational biology and bioinformatics, and served on the Board of Directors (2005–2016), and as a Vice-President (2007–2016), of the ISCB Hebrew University,

Nabil Djouder

University of Freiburg, Germany.

Nabil Djouder, born in France, obtained his PhD in Molecular Pharmacology from the University of Strasbourg (France) and the University of Freiburg (Germany), where he worked in the laboratory of K. Aktories. He studied the molecular mechanisms underlying the activation of mast cells by cross-linking high affinity antigen receptors (Fcε-RI) and the involvement of small GTPases from the Rho family in this activation.

In 2001, he moved to Basel (Switzerland) as a postdoctoral research fellow and joined the laboratory of W. Krek at the Novartis Friedrich Miescher Institute. He has since worked in the field of growth control, cancer, and associated metabolic disorders. Most of his research focuses on the mTOR/S6K pathway and the integration of growth factors, nutrients, and energy homeostasis.

Joseph Yanai

University of Colorado, US

1972 – Ph.D. Univ. of Colorado.
1978 – Present, Lecturer, Senior Lecturer; Associate Professor; Professor.
1991 – Present, Professor (Adjunct); Department of Pharmacology, Duke University Medical School, Durham, North Carolina, USA

Rony Seger

weizmann institute of science, Isreal

Rony continues to work in field of MAPK signaling and his achievements include: 1) Development of the first anti phospho antibodies for the study of MAPK activity; 2) Identification and study the role of alternatively spliced isoforms of ERKs; and 3) Elucidation of mechanisms that govern the subcellular localization of MAPK components, in particular their mechanism of nuclear translocation. 4) Use of the nuclear translocation as anti cancer and inflammation target.

He got Excellent Research Award of HKUST School of Engineering in 2012. He obtained Gold Medal and The Best Award in the Invention & Innovation Awards 2014 held at the Malaysia Technology Expo (MTE) 2014, which was hosted in Kuala Lumpur, Malaysia, on 20-22 Feb 2014. He is a Member of EU Academy of Sciences (EUAS) since July 2017.